000919.SHE Jinling Pharmaceutical Co Ltd
- Market cap
- CNY 3.67B
- P/E
- 84.3x
- P/B
- 0.97x
- ROE
- 2.1%
- Dividend yield
- 1.84%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000919.SHE undervalued?
Graham number000919.SHE trades 90.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jinling Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jinling Pharmaceutical Co Ltd yet.
Jinling Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of…
Full company profileJinling Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jinling Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.58B | 3.19B | 2.90B | 2.53B | 2.50B | 2.81B | 2.67B | 3.19B | 3.28B | 3.20B | 3.14B |
| Gross Profit | 733M | 707M | 692M | 598M | 561M | 628M | 529M | 637M | 605M | 667M | 678M |
| Operating Income | 283M | 223M | 364M | 248M | 125M | 197M | 130M | 148M | 43.0M | 36.2M | 73.6M |
| EBITDA | 396M | 344M | 487M | 370M | 245M | 317M | 251M | 299M | 187M | 232M | 112M |
| Net Income | 180M | 137M | 242M | 145M | 65.1M | 121M | 105M | 106M | 40.4M | 53.9M | 78.6M |
| EPS | 0.36 | 0.27 | 0.48 | 0.29 | 0.13 | 0.24 | 0.21 | 0.21 | 0.07 | 0.09 | 0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 3.86B | 3.86B | 3.88B | 4.16B | 4.28B | 4.45B | 4.54B | 4.55B | 6.09B | 6.01B | 6.04B |
| Total Liabilities | 805M | 803M | 639M | 734M | 850M | 913M | 916M | 866M | 1.24B | 1.18B | 1.21B |
| Shareholders' Equity | 2.54B | 2.59B | 2.74B | 2.88B | 2.86B | 2.93B | 2.99B | 3.04B | 3.79B | 3.78B | 3.77B |
| Cash & Short-term Investments | 798M | 974M | 1.02B | 1.58B | 1.32B | 1.50B | 1.59B | 1.51B | 2.48B | 1.52B | 1.46B |
| Total Debt | 115M | 139M | 29.9M | 31.9M | 39.9M | 16.7M | 5.30M | 2.55M | 185M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 96.1M | 443M | 434M | 466M | 311M | 292M | 261M | 159M | 154M | 174M | - |
| Capital Expenditure | 107M | 66.8M | 136M | 126M | 291M | 163M | 310M | 186M | 202M | 158M | 127M |
| Free Cash Flow | -11.3M | 376M | 297M | 340M | 20.1M | 129M | -49.1M | -25.9M | -47.4M | 16.3M | 189M |
| Ratios | |||||||||||
| ROE | 7.1% | 5.3% | 8.8% | 5.0% | 2.3% | 4.1% | 3.5% | 3.5% | 1.1% | 1.4% | 2.1% |
| ROA | 4.7% | 3.6% | 6.2% | 3.5% | 1.5% | 2.7% | 2.3% | 2.3% | 0.7% | 0.9% | 1.3% |
| Net Profit Margin | 5.0% | 4.3% | 8.3% | 5.7% | 2.6% | 4.3% | 3.9% | 3.3% | 1.2% | 1.7% | 2.5% |
| Debt to Equity | 0.05x | 0.05x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jinling Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.84%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 125.2%
- Ex-dividend date
- Jun 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 67.5M | 0.11 | 125.2% |
| 2024 | CNY 63.2M | 0.11 | 156.5% |
| 2023 | CNY 51.2M | 0.10 | 48.2% |
| 2022 | CNY 50.4M | 0.10 | 47.9% |
| 2021 | CNY 50.4M | 0.10 | 41.8% |
| 2020 | CNY 85.7M | 0.17 | 131.5% |
| 2019 | CNY 85.7M | 0.17 | 59.0% |
| 2018 | CNY 128M | 0.25 | 53.1% |
| 2017 | CNY 89.5M | 0.18 | 65.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jul 10, 2006.
Who owns Jinling Pharmaceutical Co Ltd
- Insiders 51.45%
- Institutions 0.69%
- Public & others 47.86%
- Shares outstanding 622M
- Free float 334M
Jinling Pharmaceutical Co Ltd company profile
- Company name
- Jinling Pharmaceutical Co Ltd
- Ticker
- 000919.SHE
- ISIN
- CNE0000010W5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 27, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,716
- Fiscal year end
- December
- Address
- Jinling Pharmaceutical Building, Nanjing, China, 210009
- Phone
- 86 25 8311 8511
- Website
- jlyy1999.com
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound bleeding and trauma hemostasis. The company also provides traditional Chinese medicines, chemical medicines, active pharmaceutical ingredients, and pharmaceutical intermediates. In addition, it engages in elderly care services, rehabilitation therapy, psychological counseling, and end-of-life care; hospital management; technical services; and healthcare investment activities. The company was incorporated in 1998 and is headquartered in Nanjing, China.
Jinling Pharmaceutical Co Ltd management
10- Mr. Hai ChenPresident & Director · born 1980
- Mr. Yang WangVP, Chief Accountant, Secretary, Financial Manager & Non-Independent Director · born 1978
- Mr. Quan LiChief Economist · born 1978
- Ms. Mingyi JiaChief Engineer · born 1973
- Mr. Jian WangExecutive Vice President · born 1973
- Mr. Jian LiVice President · born 1985
- Mr. Xinning ZhuAssistant to President · born 1971
- Mr. Zhenxin XiGeneral Manager Assistant · born 1968
- Ms. Xin LiuAssistant to the President · born 1979
- Mr. Yuan Xin FanAssistant to the President · born 1971